Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394548 | 0.83 | KDM1A (0.32) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL123283 | 0.83 | KDM1A (0.32) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL502099 | 0.82 | KDM1A (0.34) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL120449 | 0.82 | CHRNA1 (0.32) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL28892254 | 0.82 | MDM2 (0.34) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL119406 | 0.81 | ALDH1A1 (0.37) | ALDH1A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29728033 | 0.81 | ALDH1A1 (0.37) | ALDH1A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29450029 | 0.81 | NR3C2 (0.39) | — | |
| SCHEMBL502076 | 0.80 | PSEN1 (0.31) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL29845433 | 0.80 | PSEN1 (0.31) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100285965-A1 | METHODS OF IMPROVING PLANT GROWTH | BAYER CROPSCIENCE AG (DE) | 2010-11-11 | — | — | US | claimed |
| US-20130303376-A1 | METHODS OF IMPROVING PLANT GROWTH | BAYER CROPSCIENCE AG (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20100285965-A1 | METHODS OF IMPROVING PLANT GROWTH | BAYER CROPSCIENCE AG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100285965-A1 | METHODS OF IMPROVING PLANT GROWTH | BAYER CROPSCIENCE AG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100285965-A1 | METHODS OF IMPROVING PLANT GROWTH | BAYER CROPSCIENCE AG (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-2090168-A1 | Method for improving plant growth | Bayer CropScience AG (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009046837-A2 | METHODS OF IMPROVING PLANT GROWTH | BAYER CROPSCIENCE AG (DE) | 2009-04-16 | — | — | WO | disclosed |
| EP-2044841-A1 | Method for improving plant growth | Bayer CropScience AG (DE) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285965-A1 | METHODS OF IMPROVING PLANT GROWTH | MYCBP, MYB, MRPL37 | CHRNA1 4612/4885CHRNB2 4616/4885CHRNA3 4613/4885 |
| US-20130303376-A1 | METHODS OF IMPROVING PLANT GROWTH | MYCBP, MYB, MRPL37 | CHRNA1 4516/4885CHRNB2 4564/4885CHRNA3 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.